Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) shares ended the last trading session 7.3% higher at $6.32. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 12.8% gain over the past four weeks. The sudden rise in the stock price has likely been driven by the growing optimism of investors regarding the potential of the company's pipeline. Orchestra BioMed Holdings is currently developing two late-stage flagship technologies designed to address large unmet needs associated with the treatment of hypertension and atherosclerotic artery disease in ...